News | November 30, 2022
Gland Pharma to buy French pharma company Cenexi
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
The new production line is equipped with the latest advanced manufacturing system to produce quality products of Alkaloids & APIs used in a wide range of pharmaceutical applications
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Subscribe To Our Newsletter & Stay Updated
